Katarzyna Barańska, Katarzyna Niemas, Marta Wojewódzka-Mirocha, Jacek Kabat, Marek Dedecjus
{"title":"[177Lu]Lu-PSMA-617治疗激素抵抗性前列腺癌患者在其他治疗方案失败后的惊人效果。","authors":"Katarzyna Barańska, Katarzyna Niemas, Marta Wojewódzka-Mirocha, Jacek Kabat, Marek Dedecjus","doi":"10.5603/nmr.108217","DOIUrl":null,"url":null,"abstract":"<p><p>This research presents the case of a 72-year-old patient with a long history of high-grade prostate cancer (Gleason 8), previously treated with radiotherapy, hormone therapy, and chemotherapy. Due to persistent disease progression and widespread metastases, the patient was enrolled in [177Lu]Lu-PSMA-617 therapy under the Rescue Drug Therapy Access (RDTL) program. Six therapeutic cycles were administered, resulting in marked clinical improvement and a decline in prostate-specific antigen (PSA) levels from 1128.00 ng/mL to 1.68 ng/mL. Positron emission tomography/computed tomography (PET/CT) imaging using [68Ga] Ga-PSMA-11 demonstrated a favorable treatment response, with no significant adverse effects. This case highlights the potential of a theranostic approach in oncology.</p>","PeriodicalId":520725,"journal":{"name":"Nuclear medicine review. Central & Eastern Europe","volume":"28 0","pages":"61-64"},"PeriodicalIF":0.7000,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Spectacular effect of [177Lu]Lu-PSMA-617 therapy in a patient with hormone-resistant prostate cancer after failure of other therapeutic options.\",\"authors\":\"Katarzyna Barańska, Katarzyna Niemas, Marta Wojewódzka-Mirocha, Jacek Kabat, Marek Dedecjus\",\"doi\":\"10.5603/nmr.108217\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>This research presents the case of a 72-year-old patient with a long history of high-grade prostate cancer (Gleason 8), previously treated with radiotherapy, hormone therapy, and chemotherapy. Due to persistent disease progression and widespread metastases, the patient was enrolled in [177Lu]Lu-PSMA-617 therapy under the Rescue Drug Therapy Access (RDTL) program. Six therapeutic cycles were administered, resulting in marked clinical improvement and a decline in prostate-specific antigen (PSA) levels from 1128.00 ng/mL to 1.68 ng/mL. Positron emission tomography/computed tomography (PET/CT) imaging using [68Ga] Ga-PSMA-11 demonstrated a favorable treatment response, with no significant adverse effects. This case highlights the potential of a theranostic approach in oncology.</p>\",\"PeriodicalId\":520725,\"journal\":{\"name\":\"Nuclear medicine review. Central & Eastern Europe\",\"volume\":\"28 0\",\"pages\":\"61-64\"},\"PeriodicalIF\":0.7000,\"publicationDate\":\"2025-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Nuclear medicine review. Central & Eastern Europe\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.5603/nmr.108217\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Nuclear medicine review. Central & Eastern Europe","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.5603/nmr.108217","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Spectacular effect of [177Lu]Lu-PSMA-617 therapy in a patient with hormone-resistant prostate cancer after failure of other therapeutic options.
This research presents the case of a 72-year-old patient with a long history of high-grade prostate cancer (Gleason 8), previously treated with radiotherapy, hormone therapy, and chemotherapy. Due to persistent disease progression and widespread metastases, the patient was enrolled in [177Lu]Lu-PSMA-617 therapy under the Rescue Drug Therapy Access (RDTL) program. Six therapeutic cycles were administered, resulting in marked clinical improvement and a decline in prostate-specific antigen (PSA) levels from 1128.00 ng/mL to 1.68 ng/mL. Positron emission tomography/computed tomography (PET/CT) imaging using [68Ga] Ga-PSMA-11 demonstrated a favorable treatment response, with no significant adverse effects. This case highlights the potential of a theranostic approach in oncology.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
